Aldeyra Therapeutics (ALDX) Price to Book (2014 - 2026)

Aldeyra Therapeutics (ALDX) has reported Price to Book for 13 consecutive years, with 3.39 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book fell 18.47% year-over-year to 3.39; the trailing twelve-month figure through Jun 2026 stood at 3.39 (down 18.47% YoY), and the FY2025 full-year result was 7.04, up 68.01% from the prior year.
• Price to Book grew to 3.39 in Q2 2026 per ALDX's latest filing, from 2.42 in the prior quarter.
• Across five years, Price to Book topped out at 7.04 in Q4 2025 and bottomed at 1.34 in Q2 2022.
• Historically, Price to Book has averaged 3.38 across 5 years, with a median of 3.3 in 2023.
• The sharpest annual moves came in 2022 and 2025: Price to Book plunged 62.7% in 2022, then soared 216.92% in 2025.
• Over 5 years, Price to Book stood at 2.7 in 2022, then tumbled by 35.74% to 1.73 in 2023, then soared by 141.69% to 4.19 in 2024, then surged by 68.01% to 7.04 in 2025, then plunged by 51.85% to 3.39 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 3.39, 2.42, and 7.04 for Q2 2026, Q1 2026, and Q4 2025 respectively.